What is Citius Oncology, Inc.'s finished goods?

Citius Oncology, Inc. (CTOR) reported finished goods of $15.71M in Q1 2026.

How has Citius Oncology, Inc.'s finished goods changed year-over-year?

Citius Oncology, Inc.'s finished goods increased by 121.5% year-over-year, from $7.09M to $15.71M.

Completed products ready for sale, valued at the lower of cost or net realizable value.

Merck & Co.MRK

$2.21B+3.9%

Delcath SystemsDCTH

$954K-4.4%

ImmunityBio, Inc.IBRX

——

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoods.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s finished goods?: Citius Oncology, Inc. (CTOR) reported finished goods of $15.71M in Q1 2026.
How has Citius Oncology, Inc.'s finished goods changed year-over-year?: Citius Oncology, Inc.'s finished goods increased by 121.5% year-over-year, from $7.09M to $15.71M.
What does finished goods mean?: Completed products ready for sale, valued at the lower of cost or net realizable value.